A small pilot study of 9 patients with dyslipidemia and insulin resistance, tested through hyperinsulinemic euglycemic clamp (insulin dose, 200 mU/m minute), showed in all a relevant increase in insulin sensitivity (+28%; P = .008) 12 months after the switch from a PI to boosted atazanavir [43]. Here, INS is linked to metabolic syndrome.